Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856332 | 0.73 | KDR (0.51) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL29900484 | 0.73 | KDR (0.51) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL374022 | 0.73 | RAB9A (0.74) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL29631691 | 0.73 | RAB9A (0.74) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL78989 | 0.72 | PRKD3 (0.62) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL29415921 | 0.72 | PRKD3 (0.62) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL8666417 | 0.71 | KDR (0.53) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL8992187 | 0.71 | KDR (0.53) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL6626948 | 0.71 | KDR (0.53) | KDRCHEK1RAB9ANPC1CA2 | |
| SCHEMBL30174331 | 0.71 | KDR (0.53) | KDRCHEK1RAB9ANPC1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046560-B1 | STEM CELL MODULATION II | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-01-06 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| CN-111587120-A | Immunogenic compositions and uses thereof | 艾比克斯治疗私人有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10124001-B2 | Stem cell modulation II | UNIVERSITY OF CANBERRA (AU) | 2018-11-13 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| EP-3185858-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | University of Canberra (AU) | 2017-07-05 | — | — | EP | disclosed |
| US-20160354367-A1 | Stem Cell Modulation II | UNIVERSITY OF CANBERRA (AU) | 2016-12-08 | — | — | US | disclosed |
| EP-3046560-A1 | STEM CELL MODULATION II | University of Canberra (AU) | 2016-07-27 | — | — | EP | disclosed |
| WO-2016029262-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | UNIVERSITY OF CANBERRA (AU) | 2016-03-03 | — | — | WO | disclosed |
| WO-2015039187-A1 | STEM CELL MODULATION II | UNIVERSITY OF CANBERRA (AU) | 2015-03-26 | — | — | WO | disclosed |
| US-20070142401-A1 | Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation | NOVARTIS AG (CH) | 2007-06-21 | — | — | US | disclosed |
| EP-1682103-A1 | INDOLYL-PYRROLEDIONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND VASCULAR DISORDERS RELATED TO BETA-AMYLOID GENERATION AND/OR AGGREGATION | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005039549-A1 | INDOLYL-PYRROLEDIONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND VASCULAR DISORDERS RELATED TO BETA-AMYLOID GENERATION AND/OR AGGREGATION | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | KDR 934/4885CHEK1 206/4885RAB9A 1078/4885 |
| US-20070142401-A1 | Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation | PRKCH, PRKCD, PRKCZ | KDR 28/4885CHEK1 171/4885RAB9A 3924/4885 |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | KDR 1515/4885CHEK1 765/4885RAB9A 1647/4885 |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | NFATC1, PRKCQ, PRKCH | KDR 2820/4885CHEK1 290/4885RAB9A 1571/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | KDR 1515/4885CHEK1 765/4885RAB9A 1647/4885 |
| US-10124001-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | KDR 934/4885CHEK1 206/4885RAB9A 1078/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | KDR 934/4885CHEK1 206/4885RAB9A 1078/4885 |
| US-20160354367-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | KDR 934/4885CHEK1 206/4885RAB9A 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.